Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

MSI2 and TGFβR1 Expression Levels in CML Patients and Hematopoietic Cell Lines

Jaspal S Kaeda, PhD, Simone Bonecker, Iris von Wunsch-Rolshoven, Frauke Ringel, PhD, Michaela Schwarz, Bernd Dörken, MD, Ilana Zalcberg, Philipp le Coutre, MD

Blood (2014) 124 (21): 4533.

https://doi.org/10.1182/blood.V124.21.4533.4533

Published: 2014

Journal Articles

Frequency of a Highly Polymorphic Variant, S36N GFI1 , Is Increased in CML Patients

Jaspal S Kaeda, PhD, Leila Amini, BSc, Concetta Quintarelli, PhD, Iris von Wunsch-Rolshoven, Frauke Ringel, PhD, Michaela Schwarz, MD, Fabrizio Pane, MD, Bernd Dörken, MD, Philipp le Coutre, MD

Blood (2014) 124 (21): 3157.

https://doi.org/10.1182/blood.V124.21.3157.3157

Published: 2014

Journal Articles

MSI2 and HOXA9 Expression Is Significantly Increased in Patients with Primary Myelofibrosis

Jaspal S Kaeda, PhD, Jackline Ayres-Silva, Leila Amini, BSc, Iris von Wunsch-Rolshoven, Frauke Ringel, PhD, Michaela Schwarz, MD, Bernd Dörken, MD, Ilana Zalcberg, Philipp le Coutre, MD

Blood (2014) 124 (21): 1868.

https://doi.org/10.1182/blood.V124.21.1868.1868

Published: 2014

Journal Articles

Hematopoietic Cell Lines and Patient Samples Show a Correlation Between Upregulated MSI2 and BCR-ABL Expression

Jaspal S. Kaeda, PhD, Rolf Schwarzer, Robert K. Slany, PhD, Thomas Burmeister, MD, Elisabetta Vagge, Leila Amini, Frauke Ringel, PhD, Katarina Pardon, Michaela Schwarz, MD, Bernd Dörken, Franziska Jundt, MD, Philipp le Coutre, MD

Blood (2013) 122 (21): 2618.

https://doi.org/10.1182/blood.V122.21.2618.2618

Published: 2013

Journal Articles

Can Targeted Therapy for CML Still Learn From Transplant? Using Post-transplant RQ-PCR monitoring to Clarify the Importance of the Depth of Molecular Remission On the Risk of Subsequent Relapse.

Frederick Pimm, Richard Szydlo, PhD, Letizia Foroni, Francesco Dazzi, MD, Jaspal S Kaeda, PhD, Gareth Gerrard, PhD, Alistair Reid, PhD, Mikel Valganon, BSc, Edward J Kanfer, John M Goldman, MD, Dragana Milojkovic, David Marin, Jane Apperley

Blood (2012) 120 (21): 2789.

https://doi.org/10.1182/blood.V120.21.2789.2789

Published: 2012

Journal Articles

Differential Expression of SHP-1 Levels in Chronic Phase and Advanced Disease CML and in AML Patients

Jaspal S Kaeda, PhD, Christian Oberender, Daniel Neuman, Theo Kim, MD, Ken I Mills, PhD, Anna Serra, PhD, Philipp Hemmati, MD, Regina Schleede, Tim Overkamp, Frauke Ringel, PhD, Thomas Pretzsch, Seval Turkmen, MD, Michaela Schwarz, MD, Renate Arnold, MD, Bernd Dörken, MD, Philipp le Coutre, MD

Blood (2012) 120 (21): 1449.

https://doi.org/10.1182/blood.V120.21.1449.1449

Published: 2012

Journal Articles

Increased MSI2 expression Is Associated with Aggressive CML and AML

Blood (2011) 118 (21): 2516.

https://doi.org/10.1182/blood.V118.21.2516.2516

Published: 2011

Journal Articles

Effects of NVP-BSK805, a Novel JAK2 Inhibitor, on BCR-ABL and JAK2 V617F Positive Cell Lines

Frauke Ringel, PhD, Jaspal S Kaeda, PhD, FRCPath, Michaela Schwarz, MD, Peggy Grille, Bernd Dörken, Philipp D. le Coutre, MD

Blood (2011) 118 (21): 5002.

https://doi.org/10.1182/blood.V118.21.5002.5002

Published: 2011

Journal Articles

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

Timothy P. Hughes, Andreas Hochhaus, Susan Branford, Martin C. Müller, Jaspal S. Kaeda, Letizia Foroni, Brian J. Druker, François Guilhot, Richard A. Larson, Stephen G. O'Brien, Marc S. Rudoltz, Manisha Mone, Elisabeth Wehrle, Vijay Modur, John M. Goldman, Jerald P. Radich, on behalf of the IRIS investigators

Blood (2010) 116 (19): 3758–3765.

https://doi.org/10.1182/blood-2010-03-273979

Published: 2010

Journal Articles

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

David Marin, Dragana Milojkovic, Eduardo Olavarria, Jamshid S. Khorashad, Hugues de Lavallade, Alistair G. Reid, Letizia Foroni, Katayoun Rezvani, Marco Bua, Francesco Dazzi, Jiri Pavlu, Matthias Klammer, Jaspal S. Kaeda, John M. Goldman, Jane F. Apperley

Blood (2008) 112 (12): 4437–4444.

https://doi.org/10.1182/blood-2008-06-162388

Published: 2008

Journal Articles

In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib

Jamshid S. Khorashad, Dragana Milojkovic, Puja Mehta, Mona Anand, Sara Ghorashian, Alistair G. Reid, Valeria De Melo, Anna Babb, Hugues de Lavallade, Eduardo Olavarria, David Marin, John M. Goldman, Jane F. Apperley, Jaspal S. Kaeda

Blood (2008) 111 (4): 2378–2381.

https://doi.org/10.1182/blood-2007-06-096396

Published: 2008

Journal Articles

Long Term Durability of Major Molecular Responses for Patients Treated with Imatinib after Failure of Interferon-Alfa Is Equivalent to That of Patients Achieving Major Molecular Responses to Imatinib as Primary Therapy.

Hugues de Lavallade, MD, Jamshid S. Khorashad, MD, Marco Bua, MD, Dragana Milojkovic, MD, Eduardo Olavarria, MD, Alistair Reid, PhD, Jaspal S. Kaeda, PhD, John M. Goldman, DM, Jane F. Apperley, MD, David Marin, MD

Blood (2007) 110 (11): 1037.

https://doi.org/10.1182/blood.V110.11.1037.1037

Published: 2007

Journal Articles

Interferon-α or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation

Hugues de Lavallade, Jamshid S. Khorashad, Howard P. Davis, Dragana Milojkovic, Jaspal S. Kaeda, John M. Goldman, Jane F. Apperley, David Marin

Blood (2007) 110 (7): 2779–2780.

https://doi.org/10.1182/blood-2007-06-094508

Published: 2007

Journal Articles

Abnormally Small BCR-ABL Transcripts in CML Patients before and during Imatinib Treatment.

Jamshid S. Khorashad, MD, Jeffrey H. Lipton, MD, David Marin, MD, Dragana Milojkovic, MD, Nicholas C.P. Cross, PhD, Nicholas Dibb, PhD, Junia V. Melo, PhD, Suzanne Kamel-Reid, PhD, John M. Goldman, MD, Jane F. Apperley, PhD, Jaspal S. Kaeda, PhD

Blood (2006) 108 (11): 2153.

https://doi.org/10.1182/blood.V108.11.2153.2153

Published: 2006

Journal Articles

Varying Response to Imatinib in CML Patients with BCR-ABL M244V Mutation.

Jamshid S. Khorashad, MD, Mona Anand, MD, David Marin, MD, Catharina Andreasson, BSc, Sara Ghorashian, MD, Jane F. Apperley, PhD, John M. Goldman, MD, Jaspal S. Kaeda, PhD

Blood (2005) 106 (11): 1986.

https://doi.org/10.1182/blood.V106.11.1986.1986

Published: 2005

Journal Articles

How Best to Express the Results of Serial RQ-PCR Studies to Measure Minimal Residual Disease in Treated Leukaemia Patients?.

Mona Anand, MD Hammersmith Hos, Jaspal S. Kaeda, PhD Hammersmith Hos, Richard Szydlo, PhD Hammersmith Hos, Jamshid S. Khorshad, MD Hammersmith Hos, David Marin, MD Hammersmith Hos, Bryony Swale, MSc Hammersmith Hos, Sue Saunders, MSc Hammersmith Hos, Eduardo Olavarria, MD Hammersmith Hos, John M. Goldman, MD Hammersmith Hos, Jane F. Apperley, PhD Hammersmith Hos

Blood (2004) 104 (11): 1104.

https://doi.org/10.1182/blood.V104.11.1104.1104

Published: 2004

Journal Articles

Clinical Decision Making in Chronic Myeloid Leukemia Based on Polymerase Chain Reaction Analysis of Minimal Residual Disease

John M. Goldman, Jaspal S. Kaeda, Nicholas C.P. Cross, Andreas Hochhaus, Rüdiger Hehlmann

Blood (1999) 94 (4): 1484–1486.

https://doi.org/10.1182/blood.V94.4.1484

Published: 1999

NARROW

MSI2 and TGFβR1 Expression Levels in CML Patients and Hematopoietic Cell Lines

Frequency of a Highly Polymorphic Variant, S36N GFI1 , Is Increased in CML Patients

MSI2 and HOXA9 Expression Is Significantly Increased in Patients with Primary Myelofibrosis

Hematopoietic Cell Lines and Patient Samples Show a Correlation Between Upregulated MSI2 and BCR-ABL Expression

Can Targeted Therapy for CML Still Learn From Transplant? Using Post-transplant RQ-PCR monitoring to Clarify the Importance of the Depth of Molecular Remission On the Risk of Subsequent Relapse.

Differential Expression of SHP-1 Levels in Chronic Phase and Advanced Disease CML and in AML Patients

Increased MSI2 expression Is Associated with Aggressive CML and AML

Effects of NVP-BSK805, a Novel JAK2 Inhibitor, on BCR-ABL and JAK2 V617F Positive Cell Lines

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib

Long Term Durability of Major Molecular Responses for Patients Treated with Imatinib after Failure of Interferon-Alfa Is Equivalent to That of Patients Achieving Major Molecular Responses to Imatinib as Primary Therapy.

Interferon-α or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation

Abnormally Small BCR-ABL Transcripts in CML Patients before and during Imatinib Treatment.

Varying Response to Imatinib in CML Patients with BCR-ABL M244V Mutation.

How Best to Express the Results of Serial RQ-PCR Studies to Measure Minimal Residual Disease in Treated Leukaemia Patients?.

Clinical Decision Making in Chronic Myeloid Leukemia Based on Polymerase Chain Reaction Analysis of Minimal Residual Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only